BriaCell Therapeutics Corp. (NASDAQ: BCTX) Completes License Transfer for Soluble CD80
Key Developments BriaCell Therapeutics Corp. (NASDAQ: BCTX), a clinical-stage biotechnology firm dedicated to innovative cancer immunotherapies, has finalized an important asset purchase transaction. The deal, completed on March 31, 2026, involved transferring BriaCell’s exclusive license for Soluble CD80, a biologic agent designed to treat cancer, to its majority-owned subsidiary, BriaPro Therapeutics Corp. This transaction, governed by the definitive purchase agreement signed on February 4, 2026, enables BriaPro to fully develop…
